Skip to main content
Erschienen in: BMC Infectious Diseases 1/2024

Open Access 01.12.2024 | Case Report

Hepatitis E virus and Klebsiella pneumoniae co-infection detected by metagenomics next-generation sequencing in a patient with central nervous system and bloodstream Infection: a case report

verfasst von: Manman Cui, Wei Sun, Yuan Xue, Jiangnan Yang, Tianmin Xu

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2024

Abstract

Background

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide with major prevalence in the developing countries and can cause extrahepatic disease including the nervous system. Central nervous system infections caused by HEV are rare and caused by HEV together with other bacteria are even rarer.

Case presentation

A 68-year-old man was admitted to the hospital due to a headache lasting for 6 days and a fever for 3 days. Lab tests showed significantly raised indicators of inflammation, cloudy cerebrospinal fluid, and liver dysfunction. Hepatitis E virus and Klebsiella pneumoniae were identified in the blood and cerebrospinal fluid using metagenomic next-generation sequencing. The patient received meropenem injection to treat K. pneumoniae infection, isoglycoside magnesium oxalate injection and polyene phosphatidylcholine injection for liver protection. After ten days of treatment, the patient improved and was discharged from the hospital.

Conclusion

Metagenomic next-generation sequencing, which can detect various types of microorganisms, is powerful for identifying complicated infections.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
mNGS
Metagenomic next-generation sequencing
HEV
Hepatitis E virus
GBS
Guillain − Barré syndrome
CSF
Cerebrospinal fluid
ALT
Alanine aminotransferase
MRI
Magnetic resonance imaging
WBC
White blood cell
CRP
C-reactive protein
PCT
Procalcitonin
IL
Interleukin
PCR
Polymerase chain reaction

Background

The Hepatitis E virus (HEV) stands as the leading cause of acute viral hepatitis worldwide, notably in developing nations [1, 2]. According to the World Health Organization (WHO), every year there are an estimated 20 million HEV infections worldwide, leading to an estimated 3.3 million symptomatic cases of hepatitis E (https://​www.​who.​int/​en/​news-room/​fact-sheets/​detail/​hepatitis-e). Most cases of acute HEV infection resolve spontaneously and do not require treatment, life-threatening acute liver failure may occur in some cases, especially pregnant women and immunocompromised patients.
HEV infection not only triggers hepatitis but also associates with neurological issues like Guillain − Barré syndrome (GBS), neuralgic amyotrophy, and encephalitis/myelitis [3]. However, the exact mechanisms behind these neurological symptoms remain unclear. Earlier case reports have shown that HEV can be found in the cerebrospinal fluid (CSF) of patients displaying neurological symptoms [47]. Laboratory investigations revealed that HEV has the capacity to harm tight junction proteins like Claudin5, Occludin, and ZO-1 (zonula occludens-1), disrupting the blood–brain barrier and allowing entry into the cerebrospinal fluid. Additionally, HEV can replicate and proliferate within nerve cells, resulting in central nervous system infections [810].
Klebsiella pneumoniae, a Gram-negative bacterium, frequently exists in the environment. Humans, being the primary host, commonly harbor K. pneumoniae in the nasopharynx and gastrointestinal tract. In healthcare facilities, the risk of colonization and consequent infection is elevated, potentially leading to hospital-based outbreaks [11]. Individuals with compromised immune systems are particularly susceptible to various infections, with respiratory, urinary tract, and bloodstream infections being most prevalent [12]. In the context of central nervous system infections, K. pneumoniae is the primary causative agent of bacterial meningitis. Among Chinese patients diagnosed with bacterial meningitis, K. pneumoniae prevalence reached a notable 11.3% [13]. The substantial occurrence and fatality rate of K. pneumoniae-induced meningitis warrant serious attention.
To date, instances of concurrent HEV and K. pneumoniae infections have not been reported. Therefore, we present a case involving a combined infection affecting the central nervous system and bloodstream caused by both HEV and K. pneumoniae, which was successfully treated. In this case, CSF and blood samples underwent analysis through mNGS. This approach enabled the swift identification of pathogens, thus facilitating early treatment and improving the patient's prognosis.

Case presentation

A 68-year-old man suddenly experienced fever and headache, with a slightly stiff neck. He had a history of bronchiectasis for over 40 years and had frequently used ciprofloxacin and amoxicillin to treat bronchiectasis-related infections. A chest CT scan displayed bronchiectasis in the lower left lobe (Fig. 1).
On April 5, 2023, he underwent testing at the hospital. Biochemical assessments indicated heightened alanine aminotransferase (ALT: 1780 U/L), signifying severe liver damage. Magnetic resonance imaging (MRI) showcased age-related brain changes and bilateral sphenoid sinusitis. On April 7, he was transferred to the Third People’s Hospital of Changzhou. Following admission, he exhibited a peak body temperature of 40 °C, noticeable headaches, and had four instances of watery yellow diarrhea. Inflammatory markers were significantly elevated (WBC 10.03E + 09/L, CRP 100.69 mg/L, PCT 2.64 ng/ml, IL-6 114.9 pg/mL). By April 8, the cerebrospinal fluid (CSF) had a light-yellow appearance, and CSF testing revealed increased WBC count (2.126E + 09/L), predominant multinucleated cells (86.3%), heightened protein (2.86 g/L), and decreased glucose (2.00 mmol/L) and chloride (113.3 mmol/L). Further test outcomes are presented in Table 1. Based on these findings, the diagnosis pointed to a central nervous system infection, with a strong likelihood of suppurative meningitis. The patient also exhibited irregular liver function and notably elevated liver enzymes. While tests for hepatitis A, B, C, and D antibodies returned negative, the hepatitis E IgM level was 8.086 S/co, suggesting a potential HEV infection.
Table 1
Laboratory indicators on the first day of admission
CSF test
 Pressure
150mmH2O
 Paneth's test
weak positive
 WBC
2.126E + 09/L
 Mononuclear cell
13.70%
 Protein
2.86 g/L
 Glucose
2.00 mmol/L
 Cl
113.3 mmol/L
 cryptococcal antigen
Negative
 Xpert MTB
Negative
Blood routine
 WBC
10.03E + 09/L
 Neutrophil
83.00%
 Lymphocyte
8.30%
 Eosinophil
0.10%
 RBC
4.22E + 12/L
 Hemoglobin
125.0 g/L
 Platelets
95E + 09/L
 B-type natriuretic peptide
143.7 pg/mL
 CD3%
40.18%
 CD3 + 
564/μL
 CD4%
16.61%
 CD4 + 
233/μL
 CD8%
23.82%
 CD8 + 
334/μL
 CD19%
5.69%
 CD19 + 
80/μL
Biochemistry
 Globulin
23.3 g/L
 Glucose
6.30 mmol/L
 CRP
100.69 mg/L
 Amyloid A
378.70 mg/L
 Uric acid
162.3μmol/l
 Ca
1.95 mmol/L
 Iron
5.14μmol/L
 D-dimer
2.27μg/ml
 PCT
2.64 ng/ml
 IL-6
114.9 pg/mL
Coagulation system
 PT
13.50 S
 PT-INR
1
Virological examination
 HBc Ab
Negative
 HAV Ab
Negative
 HCV Ab
Negative
 HDV Ab
Negative
 HGV Ab
Negative
 HIV Ab
Negative
 HEV IgM
7.750 S/co
 HEV IgG
Negative
Liver function
 Alanine aminotransferase (ALT)
423.9 U/L
 Aspartate aminotransferase (AST)
53 U/L
 Alkaline phosphatase
235 U/L
 Gamma-glutamyl transferase (GGT)
241.2 U/L
 Total bilirubin
17.7 μmol/L
 Direct bilirubin
11.6 μmol/L
 Total protein
52.0 g/L
 Albumin
28.7 g/L
 Prealbumin
5.4 mg/dL
 Glycocholic acid
18.4 mg/L
 Total bile acid
27.3 μmol/L
Considering the seriousness of central nervous system infection, traditional detection and mNGS were applied for blood and CSF samples. On April 9, mNGS analysis of both CSF and peripheral blood unveiled an infection involving K. pneumoniae and HEV, as illustrated in Fig. 2. Quantitative real-time PCR assessment of HEV in peripheral blood (HEV-RNA) indicated a viral load of 1.8E + 04 copies/ml, and in feces (HEV-RNA), a viral load of 8.4E + 03 copies/ml. On April 19, the peripheral blood culture results from the previous hospital were obtained and confirmed K. pneumoniae infection (which was only resistant to ampicillin and was sensitive to amoxicillin, clavulanate, tobramycin, gentamicin, amikacin, chloramphenicol, cefazolin, cefathiamidine, cefuroxime, cetohexazine, piperacillin tazobactam, aztreonam, meropenem, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, trimethoprim and sulfamethoxazole.).
On the day of admission, the patient received treatment with isoglycoside magnesium oxalate injection (150 mg once daily), polyene phosphatidylcholine injection (697.5 mg once daily) for liver protection, and was administered mannitol (150 ml every 6 h) and glycerol fructose (150 ml every 12 h) to reduce intracranial pressure. Additionally, the patient received linezolid glucose injection (0.6 g every 12 h) and meropenem injection (2 g every 8 h) to empiric anti-infection therapy. Dexamethasone injection was given at a dose of 5 mg once daily for 7 days for its anti-inflammatory effects. The patient also took the oral powder (0.5 g twice daily) containing Saccharomyces Boulardii CNCM I-745, a fungal probiotic, to regulate intestinal flora and alleviated diarrhea symptom. Based on the result of CSF mNGS on April 9, linezolid was stopped. On April 19, the anti-infection medication was changed to ceftazidime injection (2 g every 8 h) until the patient was discharged on April 26.
Following treatment, the patient's fever subsided, and the headache improved. Re-examinations indicated a reduction in inflammation markers and improved liver function. A CSF test performed on April 18 showed clear and colorless fluid with a pressure of 95 mmH2O. On April 19, PCR testing did not detect HEV-RNA in the patient's serum and blood. All indicators were found to be within the normal range, as depicted in Table 2.
Table 2
Laboratory indicators during hospitalization
 
4/5
4/8
4/9
4/10
4/11
4/12
4/13
4/17
4/22
WBC(E + 09/L)
14
10.03
10.01
6.51
8.47
7.51
9.07
7.71
5.39
N(E +09/L))
12.3
8.33
7.51
5.59
6.4
4.79
5.35
5.1
2.74
CRP(mg/L)
37.5
100.69
74.6
39.47
19.39
12.55
9.84
6.52
1.37
2003PCT(ng/ml)
4.73
2.64
2.09
1.51
0.72
0.43
   
IL-6(pg/mL)
 
114.9
   
16
   
SAA(mg/L)
 
378.7
298.4
104
18.3
5.4
9.8
8.2
2.3
ALT(U/L)
1780
378.7
267
 
206.6
 
168.5
88
40
AST(U/L)
596
423.9
32
 
59
 
45
29
24
ALP(U/L)
327
53
216
 
202
 
209
220
201
GGT(U/L)
292
235
201
 
207
 
214
192
145
LDH(U/L)
375
241
158
 
146
 
165
176
144
TBIL(μmol/L)
19.8
201
15.5
 
10.3
 
7.5
9.3
10.9
ALB(g/L)
40.5
17.7
25.7
 
26.1
 
29
32.4
36.1

Discussion and conclusions

We present an unusual case involving simultaneous infections with hepatitis E virus and Klebsiella pneumoniae in both the central nervous system and bloodstream. The presence of positive Anti-HEV IgM test results and the detection of nucleic acid in peripheral blood, feces, and cerebrospinal fluid affirmed the diagnosis of acute hepatitis. Concurrently, there were significantly elevated levels of inflammatory markers upon admission. The cerebrospinal fluid displayed turbidity, and tests indicated acute suppurative meningitis. mNGS confirmed the presence of both HEV and K. pneumoniae in both cerebrospinal fluid and blood samples, establishing infections in both the central nervous system and bloodstream.
The transmission of Hepatitis E virus typically occurs via the gastrointestinal tract. Prior to the onset of symptoms, the patient attended a large banquet, which could potentially be the source of infection. Hepatitis E virus frequently manifests as acute liver inflammation accompanied by gastrointestinal symptoms such as fever, nausea, abdominal distension, and diarrhea. These symptoms correspond to the initial ones observed in the patient.
Upon entering the human body through the gastrointestinal tract, recent research suggests that HEV initially replicates in intestinal cells. Subsequently, it infects hepatocytes, and then spreads into the bloodstream, where it targets extrahepatic cells, including nerve cells. Upon release from the apical side, HEV is excreted through feces and urine [14]. By the 8th day of the disease's progression, varying levels of HEV were detected in the feces and peripheral blood. However, on the 18th day, no HEV was detectable, aligning with findings from previous studies [15].
Although HEV is primarily regarded as a virus that targets the liver, it can also lead to infections in the central nervous system by crossing the blood–brain barrier. In this instance, HEV was additionally identified in the cerebrospinal fluid, signifying an infection within the central nervous system.
Klebsiella pneumoniae holds significance within the Klebsiella genus of the Enterobacteriaceae family, commonly found in both the upper respiratory tract and the intestinal tract of humans. This bacterium assumes the role of an opportunistic pathogen, often linked to hospital-acquired infections [16, 17]. It primarily impacts individuals in hospital settings or those with compromised immune systems, particularly patients with pre-existing conditions like liver disease and diabetes [18].
The patient's counts of CD3 + total T cells, CD4 + helper T cells, and CD19 + B lymphocytes have all seen notable reductions, suggesting a deficiency in cellular immunity. This deficiency could heighten the risk of co-infection involving the HEV and K. pneumoniae. While the sequence of infections remains uncertain, it is posited that the patient might have initially contracted the Hepatitis E virus. This, in turn, could have caused diarrhea and significant liver dysfunction, thus permitting K. pneumoniae to breach the intestinal mucosal barrier, enter the bloodstream, and subsequently traverse the blood–brain barrier, resulting in an infection within the central nervous system.
Infections of the nervous system are potential life-threatening and prompt recognition and treatment of a central nervous system(CNS) infection is crucial for patient survival, as these infections have a high morbidity and mortality. Because of notable advantages in terms of timeliness and sensitivity, mNGS has a great diagnostic value in CNS infections and had an overall superior detection rate to culture [1921]. In this case, mNGS successfully detected K. pneumoniae and HEV in CSF, while the culture results were negative. This case suggests that mNGS may be a useful diagnostic tool for CNS infection.
We present an exceptional case involving the simultaneous infection of the Hepatitis E virus and K. pneumoniae detected within a patient's cerebrospinal fluid and Peripheral blood. This case underscores the advantages of mNGS in the context of intricate infections.

Acknowledgements

We sincerely thank Dinfectome Inc., Nanjing, China, for providing the help in mNGS sequencing and results interpretation.

Declarations

The studies involving human participants were reviewed and approved by Ethics Committee of the Third People’s Hospital of Changzhou.
Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086.
2.
Zurück zum Zitat European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL clinical practice guidelines on Hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.CrossRef European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL clinical practice guidelines on Hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.CrossRef
3.
Zurück zum Zitat Dalton HR, Kamar N, van Eijk JJJ, McLean BN, Cintas P, Bendall RP, Jacobs BC. Hepatitis E virus and neurological injury. Nat Reviews Neurol. 2015;12(2):77–85.CrossRef Dalton HR, Kamar N, van Eijk JJJ, McLean BN, Cintas P, Bendall RP, Jacobs BC. Hepatitis E virus and neurological injury. Nat Reviews Neurol. 2015;12(2):77–85.CrossRef
4.
Zurück zum Zitat Abravanel F, Nicot F, Lhomme S, Cazabat M, Drumel T, Velay A, Latour J, Belliere J, Cintas P, Kamar N, et al. Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. Vaccines. 2021;9(10):1205.CrossRefPubMedPubMedCentral Abravanel F, Nicot F, Lhomme S, Cazabat M, Drumel T, Velay A, Latour J, Belliere J, Cintas P, Kamar N, et al. Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. Vaccines. 2021;9(10):1205.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, Rostaing L. Hepatitis E Virus‐Induced neurological symptoms in a kidney‐transplant patient with chronic Hepatitis. Am J Transplant. 2010;10(5):1321–4.CrossRefPubMed Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, Rostaing L. Hepatitis E Virus‐Induced neurological symptoms in a kidney‐transplant patient with chronic Hepatitis. Am J Transplant. 2010;10(5):1321–4.CrossRefPubMed
6.
Zurück zum Zitat Rahmig J, Grey A, Berning M, Schaefer J, Lesser M, Reichmann H, Puetz V, Barlinn K, Siepmann T. Disseminated inflammation of the central nervous system associated with acute hepatitis E: a case report. BMC Neurol. 2020;20(1):391.CrossRefPubMedPubMedCentral Rahmig J, Grey A, Berning M, Schaefer J, Lesser M, Reichmann H, Puetz V, Barlinn K, Siepmann T. Disseminated inflammation of the central nervous system associated with acute hepatitis E: a case report. BMC Neurol. 2020;20(1):391.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Salim OJ, Davidson A, Li K, Leach JP, Heath C. Brainstem encephalitis and acute polyneuropathy associated with hepatitis E Infection. BMJ Case Rep. 2017;2017:bcr2017220799. Salim OJ, Davidson A, Li K, Leach JP, Heath C. Brainstem encephalitis and acute polyneuropathy associated with hepatitis E Infection. BMJ Case Rep. 2017;2017:bcr2017220799.
8.
Zurück zum Zitat Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, van der Kroeg M, Zhao M, Yin Y, Wang W, et al. Hepatitis E Virus infects neurons and brains. J Infect Dis. 2017;215(8):1197–206.CrossRefPubMed Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, van der Kroeg M, Zhao M, Yin Y, Wang W, et al. Hepatitis E Virus infects neurons and brains. J Infect Dis. 2017;215(8):1197–206.CrossRefPubMed
9.
Zurück zum Zitat Fritz M, Berger B, Schemmerer M, Endres D, Wenzel JJ, Stich O, Panning M. Pathological cerebrospinal fluid findings in patients with neuralgic amyotrophy and Acute Hepatitis E virus Infection. J Infect Dis. 2018;217(12):1897–901.CrossRefPubMed Fritz M, Berger B, Schemmerer M, Endres D, Wenzel JJ, Stich O, Panning M. Pathological cerebrospinal fluid findings in patients with neuralgic amyotrophy and Acute Hepatitis E virus Infection. J Infect Dis. 2018;217(12):1897–901.CrossRefPubMed
10.
Zurück zum Zitat Tian J, Shi R, Liu T, She R, Wu Q, An J, Hao W, Soomro MH. Brain Infection by Hepatitis E Virus probably via damage of the blood-brain barrier due to alterations of tight Junction proteins. Front Cell Infect Microbiol. 2019;9:9.CrossRef Tian J, Shi R, Liu T, She R, Wu Q, An J, Hao W, Soomro MH. Brain Infection by Hepatitis E Virus probably via damage of the blood-brain barrier due to alterations of tight Junction proteins. Front Cell Infect Microbiol. 2019;9:9.CrossRef
11.
Zurück zum Zitat Hu F, Yang F, Wang M, Xu X, Yang Y, Ding B, Zhu J, Hao M, Wu S, Qin X. The colonization of Carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to Intensive Care Units in China. J Infect Dis. 2020;221(Supplement2):206-S214. Hu F, Yang F, Wang M, Xu X, Yang Y, Ding B, Zhu J, Hao M, Wu S, Qin X. The colonization of Carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to Intensive Care Units in China. J Infect Dis. 2020;221(Supplement2):206-S214.
12.
Zurück zum Zitat Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589–603.CrossRefPubMedPubMedCentral Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589–603.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Huang N, Jia H, Zhou B, Zhou C, Cao J, Liao W, Liu S, Wang L, Chen L, Chen L, et al. Hypervirulent carbapenem-resistant Klebsiella pneumoniae causing highly fatal meningitis in southeastern China. Frontiers in Public Health. 2022;10:991306.CrossRefPubMedPubMedCentral Huang N, Jia H, Zhou B, Zhou C, Cao J, Liao W, Liu S, Wang L, Chen L, Chen L, et al. Hypervirulent carbapenem-resistant Klebsiella pneumoniae causing highly fatal meningitis in southeastern China. Frontiers in Public Health. 2022;10:991306.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Mallet V, Scarano Pereira J-P, Martinino A, Roque-Afonso A-M. The rise of the hepatitis E virus. J Hepatol. 2021;75(6):1491–3.CrossRefPubMed Mallet V, Scarano Pereira J-P, Martinino A, Roque-Afonso A-M. The rise of the hepatitis E virus. J Hepatol. 2021;75(6):1491–3.CrossRefPubMed
15.
Zurück zum Zitat Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti G, Bihl F, et al. Neurologic Complications of acute hepatitis E virus Infection. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e643.CrossRefPubMedPubMedCentral Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti G, Bihl F, et al. Neurologic Complications of acute hepatitis E virus Infection. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e643.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Luo K, Tang J, Qu Y, Yang X, Zhang L, Chen Z, Kuang L, Su M, Mu D. Nosocomial Infection by Klebsiella pneumoniae among neonates: a molecular epidemiological study. J Hosp Infect. 2021;108:174–80.CrossRefPubMed Luo K, Tang J, Qu Y, Yang X, Zhang L, Chen Z, Kuang L, Su M, Mu D. Nosocomial Infection by Klebsiella pneumoniae among neonates: a molecular epidemiological study. J Hosp Infect. 2021;108:174–80.CrossRefPubMed
17.
Zurück zum Zitat Gorrie CL, Mirčeta M, Wick RR, Judd LM, Lam MMC, Gomi R, Abbott IJ, Thomson NR, Strugnell RA, Pratt NF, et al. Genomic dissection of Klebsiella pneumoniae infections in hospital patients reveals insights into an opportunistic pathogen. Nature Communications. 2022;13(1):3017.CrossRefPubMedPubMedCentral Gorrie CL, Mirčeta M, Wick RR, Judd LM, Lam MMC, Gomi R, Abbott IJ, Thomson NR, Strugnell RA, Pratt NF, et al. Genomic dissection of Klebsiella pneumoniae infections in hospital patients reveals insights into an opportunistic pathogen. Nature Communications. 2022;13(1):3017.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–59.CrossRefPubMed Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–59.CrossRefPubMed
19.
Zurück zum Zitat Zhang Y, Cui P, Zhang HC, Wu HL, Ye MZ, Zhu YM, Ai JW, Zhang WH. Clinical application and evaluation of metagenomic next-generation sequencing in suspected adult central nervous system Infection. J Transl Med. 2020;18(1):199.CrossRefPubMedPubMedCentral Zhang Y, Cui P, Zhang HC, Wu HL, Ye MZ, Zhu YM, Ai JW, Zhang WH. Clinical application and evaluation of metagenomic next-generation sequencing in suspected adult central nervous system Infection. J Transl Med. 2020;18(1):199.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Miller S, Naccache SN, Samayoa E, Messacar K, Arevalo S, Federman S, Stryke D, Pham E, Fung B, Bolosky WJ, et al. Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. Genome Res. 2019;29(5):831–42.CrossRefPubMedPubMedCentral Miller S, Naccache SN, Samayoa E, Messacar K, Arevalo S, Federman S, Stryke D, Pham E, Fung B, Bolosky WJ, et al. Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. Genome Res. 2019;29(5):831–42.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhang S, Wu G, Shi Y, Liu T, Xu L, Dai Y, Chang W, Ma X. Understanding etiology of community-acquired central nervous system Infections using metagenomic next-generation sequencing. Front Cell Infect Microbiol. 2022;12:979086.CrossRefPubMedPubMedCentral Zhang S, Wu G, Shi Y, Liu T, Xu L, Dai Y, Chang W, Ma X. Understanding etiology of community-acquired central nervous system Infections using metagenomic next-generation sequencing. Front Cell Infect Microbiol. 2022;12:979086.CrossRefPubMedPubMedCentral
Metadaten
Titel
Hepatitis E virus and Klebsiella pneumoniae co-infection detected by metagenomics next-generation sequencing in a patient with central nervous system and bloodstream Infection: a case report
verfasst von
Manman Cui
Wei Sun
Yuan Xue
Jiangnan Yang
Tianmin Xu
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2024
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08850-4

Weitere Artikel der Ausgabe 1/2024

BMC Infectious Diseases 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.